摘要
骨髓间充质干细胞治疗是治疗各种疾病和损伤的有力工具。然而,重要的限制,包括体内应用所需的大量细胞以及与年龄有关的寿命、增殖和效力下降,可能阻碍了骨髓间充质干细胞在患者中的应用。在这方面,基因疗法可能为优化骨髓间充质干细胞在再生医学中的应用提供强有力的途径。不同的病毒和非病毒基因的车辆已被操纵基因修饰MSCs,其中非常有效的和相对安全的重组腺相关病毒(AAV)载体,成为首选用于治疗人类疾病的基因传递系统。然而,这种基因的车辆可以通过几个障碍临床适应有限,包括传播非靶位点的可能性和在宿主生物体可能会影响他们的治疗作用的免疫毒性反应的存在。智能生物材料作为提高时间和空间在目标地点和/或作为MSC生长的脚手架是一个创新的治疗剂演示接口的使用,为了克服这些缺点,否则抑制强效细胞群的疗效的重要途径。在这里,我们提供基于生物材料作为靶细胞的重组腺相关病毒载体直接在收件人使用车辆最近的组织工程方法的概述(体内策略)或作为rAAV支持矩阵修饰骨髓间充质干细胞间接细胞再植术(体外战略)为手段来激活的肌肉骨骼系统。组织修复过程
关键词: 重组腺相关病毒,MSCs,组织工程,生物材料,肌肉骨骼系统,组织修复。
Current Gene Therapy
Title:Smart and Controllable rAAV Gene Delivery Carriers in Progenitor Cells for Human Musculoskeletal Regenerative Medicine with a Focus on the Articular Cartilage
Volume: 17 Issue: 2
关键词: 重组腺相关病毒,MSCs,组织工程,生物材料,肌肉骨骼系统,组织修复。
摘要: Cell therapy using mesenchymal stem cells (MSCs) is a powerful tool for the treatment of various diseases and injuries. Still, important limitations including the large amounts of cells required for application in vivo and the age-related decline in lifespan, proliferation, and potency may hinder the use of MSCs in patients. In this regard, gene therapy may offer strong approaches to optimize the use of MSCs for regenerative medicine. Diverse nonviral and viral gene vehicles have been manipulated to genetically modify MSCs, among which the highly effective and relatively safe recombinant adeno-associated viral (rAAV) vectors that emerged as the preferred gene delivery system to treat human disorders. Yet, clinical adaptation of such gene vehicles may be limited by several hurdles, including the possibility of dissemination to nontarget sites and the presence of immune and toxic responses in the host organism that may impair their therapeutic actions. The use of smart biomaterials acting as interfaces to enhance the temporal and spatial presentation of therapeutic agents in the target place and/or acting as scaffolding for MSC growth is an innovative, valuable approach to overcome these shortcomings that else restrain the efficacy of such potent cell populations. Here, we provide an overview on the most recent tissue engineering approaches based on the use of biomaterials acting as vehicles for rAAV vectors to target MSCs directly in the recipient (in vivo strategy) or as supportive matrices for rAAV-modified MSCs for indirect cell reimplantation (ex vivo strategy) as means to activate the reparative processes in tissues of the musculoskeletal system.
Export Options
About this article
Cite this article as:
Smart and Controllable rAAV Gene Delivery Carriers in Progenitor Cells for Human Musculoskeletal Regenerative Medicine with a Focus on the Articular Cartilage, Current Gene Therapy 2017; 17 (2) . https://dx.doi.org/10.2174/1566523217666170510162459
DOI https://dx.doi.org/10.2174/1566523217666170510162459 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements